此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估富血小板血浆治疗雄激素性脱发的疗效

2026年11月4日 更新者:Wake Forest University Health Sciences

The study team will assess the efficacy of platelet-rich plasma therapy, a special blood product which is from the participant's own body, in the treatment of androgenic alopecia (also known as male pattern hair loss) in females.

研究概览

详细说明

Androgenic alopecia, or male-pattern hair loss affects both men and women. This hair loss pattern is typically characterized by thinning at the crown of scalp and/or M-shaped hair line in males or diffuse thinning throughout in females. Platelet-rich plasma (PRP) therapy has recently been studied as a hair rejuvenation therapy in patients with non-inflammatory alopecia. Though the mechanism of action is not well understood, PRP is thought to promote angiogenesis and enhance blood flow around hair follicles via platelet-derived growth factor (PDGF), transforming growth factor (TGF), and vascular endothelial growth factor (VEGF). The primary objective of the study is to determine whether PRP, administered once monthly for 3 months improves clinical outcomes and quality of life in females with androgenic alopecia. This is a randomized, placebo-controlled, double-blind, half-head, single center clinical study where sixteen subjects with androgenic alopecia will be recruited. Dermatology Life Quality Index will be assessed at several time points. Disease severity will be measured using the Severity of Alopecia Tool (SALT), Alopecia Density and Extent Score (ALODEX); Trichoscan images will be captured to document participants' clinical progress. Adverse events will be recorded at each visit, treatment will be discontinued if any subject experience a serious adverse event. Treatment visits will take place at baseline, 4 weeks (1 month), 8 weeks (2 months), and 12 weeks (3 month). A follow-up, non-treatment visit will take place at 24 weeks (6 months). The study team hypothesizes that PRP will improve DLQI, SALT, ALODEX, hair count (number of hairs/0.65 cm2), hair density (number of hairs/cm2), hair diameter, anagen to telogen ratio, and vellus hair to terminal hair ratio in female subjects with androgenic alopecia.

研究类型

介入性

注册 (估计的)

16

阶段

  • 第一阶段早期

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • North Carolina
      • Winston-Salem、North Carolina、美国、27104
        • Wake Forest University Baptist Health

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Female ≥18 years of age at baseline visit.
  • Documentation of androgenic alopecia diagnosis as evidenced by one or more clinical features
  • Not currently on any treatment for alopecia, or has undergone 2-week washout period if recently on medication(s) for alopecia
  • Written informed consent obtained from subject and ability for subject to comply with the requirements of the study

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  • Have an infection, metastatic disease or certain skin conditions (ie. Psoriasis) which could worsen or spread with injections
  • Diagnosed with a blood or bleeding disorder
  • Diagnosed with anemia
  • Currently on anticoagulant therapy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Group A

At the baseline visit subjects will be randomized to either group A or group B. Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.

Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.

实验性的:Group B

At the baseline visit subjects will be randomized to either group A or group B. Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.

Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Severity of Alopecia Tool (SALT) from baseline
大体时间:6 months

Change in Severity of Alopecia Tool (SALT) from baseline.

SALT scoring - This calculation is based on a scoring system. The scalp is divided into the following 4 areas:

Vertex: 40% (0.4) of scalp surface area. Right profile of scalp: 18% (0.18) of scalp surface area. Left profile of scalp: 18% (0.18) of scalp surface area. Posterior aspect of scalp: 24% (0.24) of scalp surface area. Percentage of hair loss in any of these areas is the percentage hair loss multiplied by percent surface area of the scalp in that area.

SALT score is the sum of percentage of hair loss in all the above-mentioned areas. For e.g., if the percentage hair loss in vertex, right profile, left profile and posterior aspect is 20, 30, 40 and 50% respecively; then, SALT score = (20 ´ 0.4) = (30 ´ 0.18) + (40 ´ 0.18) + (50 ´ 0.24) = 8+5.4+7.2+12 = 32.6 Lower score denote better outcomes.

6 months

次要结果测量

结果测量
措施说明
大体时间
Change in Hair Count (number of hairs/0.65cm^2)
大体时间:6 months

Change in Hair Count (number of hairs/0.65cm^2), as assessed via Trichoscan

6 months
Change in Hair Density (number of hairs/cm^2)
大体时间:6 months

Change in Hair Density (number of hairs/cm^2), as assessed via Trichoscan

6 months

其他结果措施

结果测量
措施说明
大体时间
Change in Hair Diameter
大体时间:6 months

Change in Hair Diameter, as assessed via Trichoscan

6 months
Anagen to Telogen Ratio
大体时间:6 months

Anagen to Telogen Ratio, as assessed via Trichoscan

6 months
Vellus Hair to Terminal Hair Ratio
大体时间:6 months

Vellus Hair to Terminal Hair Ratio, as assessed via Trichoscan

6 months
Change in Dermatology Life Quality Index (DLQI)
大体时间:6 months

Change in Dermatology Life Quality Index (DLQI)

10 question are asked pertaining to symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment.

The scoring of each answer is as follows:

Very much scored 3 A lot scored 2 A little scored 1 Not at all scored 0 Not relevant scored 0 Question unanswered scored 0 Question 7: "prevented work or studying" scored 3 The DLQI is calculated by adding the score of each question. The maximum score is 30 and the minimum is 0. The higher the score, the more quality of life is impaired.

Meaning of DLQI Scores 0-1 = no effect at all on patient's life 2-5 = small effect on patient's life 6-10 = moderate effect on patient's life 11-20 = very large effect on patient's life 21-30 = extremely large effect on patient's life

6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Rita Pichardo, MD、Wake Forest University School of Medicine, Department of Dermatology

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2027年7月1日

研究完成 (估计的)

2027年7月1日

研究注册日期

首次提交

2018年3月15日

首先提交符合 QC 标准的

2018年3月15日

首次发布 (实际的)

2018年3月22日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅